GSK
GSK
813 hedge funds and large institutions have $10B invested in GSK in 2022 Q4 according to their latest regulatory filings, with 168 funds opening new positions, 235 increasing their positions, 275 reducing their positions, and 80 closing their positions.
167% more call options, than puts
Call options by funds: $420M | Put options by funds: $157M
110% more first-time investments, than exits
New positions opened: 168 | Existing positions closed: 80
28% more capital invested
Capital invested by funds: $7.84B → $10B (+$2.2B)
23% more funds holding in top 10
Funds holding in top 10: 13 → 16 (+3)
10% more funds holding
Funds holding: 742 → 813 (+71)
0.22% more ownership
Funds ownership: 6.57% → 6.78% (+0.22%)
15% less repeat investments, than reductions
Existing positions increased: 235 | Existing positions reduced: 275
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JEST
JTC Employer Solutions Trustee
St Helier,
Jersey
|
+$442M |
| 2 |
Dodge & Cox
San Francisco,
California
|
+$211M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$200M |
| 4 |
Primecap Management
Pasadena,
California
|
+$111M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$69.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$326M |
| 2 |
Two Sigma Investments
New York
|
-$219M |
| 3 |
Renaissance Technologies
New York
|
-$100M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$92.5M |
| 5 |
Two Sigma Advisers
New York
|
-$77.2M |
GSK Hedge Fund Activity: Q4 2022 in Review
813 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2022, worth a combined $10B — up 28% from $7.84B a quarter earlier.
Buyers outnumbered sellers: 168 funds opened new GSK positions and 80 closed out — a net gain of 88 holders — while 235 added to existing stakes and 275 trimmed.
The largest buyer was JTC Employer Solutions Trustee, adding an estimated $442M. The largest seller was Capital International Investors, exiting entirely with an estimated $326M sold.
- 813 institutional investors held GSK (GSK) as of Q4 2022, up from 742 in Q3 2022.
- Funds reported $10B of GSK stock for Q4 2022, up 28% quarter-over-quarter.
- 168 funds opened new GSK positions in Q4 2022 and 80 closed out, a net change of +88 holders.
- The largest GSK buyer in Q4 2022 was JTC Employer Solutions Trustee, an estimated $442M added.
- The largest GSK seller in Q4 2022 was Capital International Investors, an estimated $326M sold.
Based on aggregated 13F filings for Q4 2022.